Page last updated: 2024-12-04

bunitrolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bunitrolol: was heading 1975-94 (see under PROPANOLAMINES 1975-90); KO 1366 was see BUNITROLOL 1975-94; use PROPANOLAMINES to search BUNITROLOL 1975-94; a beta-adrenergic receptor antagonist with weak antiarrhythmic activity and minor ability to decrease the heart rate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2473
CHEMBL ID418134
CHEBI ID135012
SCHEMBL ID34720
MeSH IDM0225267

Synonyms (38)

Synonym
34915-68-9
2-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)benzonitrile
brn 2374567
o-(3-(tert-butylamino)-2-hydroxypropoxy)benzonitrile
ko 1366
2-propanol, 3-(tert-butylamino)-1-(m-cyanophenoxy)-
2-nitrilo-n-tert-butylphenoxypropanolamine
benzonitrile, 2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-
(rs)-2-(3-(tert-butylamino)-2-hydroxypropoxy)benzonitril
benzonitrile, o-(3-(tert-butylamino)-2-hydroxypropoxy)-
bunitrolol [inn]
bunitrololum [inn-latin]
ko-1366
bunitrolol
CHEBI:135012
CHEMBL418134
2-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile
AKOS007930876
f2613lo055 ,
bunitrololum
unii-f2613lo055
bunitrolol [who-dd]
(+/-)-1-(2-cyanophenoxy)-2-hydroxy-3-tert-butylaminopropane
1-(2-cyanophenoxy)-2-hydroxy-3-tert-butylaminopropane
bunitrolol [mi]
SCHEMBL34720
1-(2-cyanophenoxy)-2-hydroxy-3-tert.-butylamino propane
VCVQSRCYSKKPBA-UHFFFAOYSA-N
2-(3-(tert-butylamino)-2-hydroxypropoxy)benzonitrile
DTXSID2022701
benzonitrile, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-
FT-0727205
Q15634020
NCGC00532503-01
EN300-1268038
CS-0079354
HY-121045
Z666346218
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID41488Selectivity for beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID679283TP_TRANSPORTER: intracellular accumulation in KB cell and KB-VJ300 cells1999Biopharmaceutics & drug disposition, Mar, Volume: 20, Issue:2
Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
AID678900TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse1999Biopharmaceutics & drug disposition, Mar, Volume: 20, Issue:2
Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
AID40539Selectivity for beta-1 receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID41891Tested for intrinsic sympathomimetic activity (ISA); antagonist with partial agonistic properties1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.56)18.7374
1990's12 (66.67)18.2507
2000's4 (22.22)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.78 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]